Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III evaluation of FLUAD-H5N1 (AFLUNOV) schedules in adults
2008-003008-72Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Audenz in Influenza A infection (4 arms), sponsored by Novartis. Primary endpoints: Magnitude of antibody response after two doses and Safety of FLUAD-H5N1. Started Aug 2008; status: completed.
02
Drugs
Audenz
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on 2008-003008-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003008-72.